Abstract:Annexin IV (ANXA4) is highly expressed in ovarian clear cell carcinoma (OCCC); however, its underlying molecular mechanism in OCCC remains unknown. The present study aimed to identify the molecule that ANXA4 may act on and to determine its underlying molecular mechanism. Immunohistochemistry, co-immunoprecipitation and western blotting were performed to detect the expression and interaction of ANXA4, and its associated proteins. Furthermore, MTT assay, flow cytometry, western blotting and gene expression profile enrichment analysis were performed to identify the potential role and molecular mechanism of ANXA4 in OCCC. The results demonstrated that ANXA4 and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kappa B) p50 nuclear expression levels were significantly higher in OCCC tissues compared with other subtypes of ovarian cancer, such as serous and mucinous. In addition, a significantly positive correlation was observed between ANXA4 and NF-kappa B p50 expression in OCCC; however, the expression levels of mutant p53 and ANXA4 were negatively correlated in a linear manner. These results suggest that ANXA4 and NF-kappa B p50 may be potential independent risk factors for poor prognosis. ANXA4 and NF-kappa B p50 were demonstrated to interact and their expression was co-localized. The cBioPortal database was used to construct a protein-protein interaction network between ANXA4, NF-kappa B p50 and p53, and functional pathway analysis indicated that the genes were predominantly enriched in the cell cycle and during apoptosis. Transfection of the ANXA4 gene increased the expression of NF-kappa B p50, as well as its downstream targets, Cyclin D1 and B-cell lymphoma-2 (Bcl-2). Furthermore, transfection of the ANXA4 gene increased proliferation and decreased apoptosis of OCCC cells. Treatment with the NF-kappa B inhibitor, BAY 11-7082, decreased Cyclin D1 and Bcl-2 expression levels. Collectively, the results of the present study suggest that wild p53 activates ANXA4 transcription, promotes its expression and enhances NF-kappa B p50 and ANXA4 interaction. This in turn activates the NF-kappa B signaling pathway, promotes cell cycle progression and inhibits apoptosis, thus contributing to the malignant progression of OCCC. Thus, ANXA4 and NF-kappa B p50 may be used as prognostic biomarkers, and may be molecular therapeutic targets in OCCC.

ALKBH5 activates CEP55 transcription through m6A demethylation in FOXP2 mRNA and expedites cell cycle entry and EMT in ovarian cancer

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer

CEP55 Promotes the Proliferation and Invasion of Tumour Cells Via the AKT Signalling Pathway in Osteosarcoma

ALKBH5 activates FAK signaling through m6A demethylation in ITGB1 mRNA and enhances tumor-associated lymphangiogenesis and lymph node metastasis in ovarian cancer

ALOX5 induces EMT and promotes cell metastasis via the LTB4/BLT2/PI3K/AKT pathway in ovarian cancer

Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma

ALKBH5 Controls the Meiosis-Coupled Mrna Clearance in Oocytes by Removing the N 6-Methyladenosine Methylation

FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer

Expression and molecular profiles of the AlkB family in ovarian serous carcinoma

p53 and ANXA4/NF-B p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma

KDM1A-mediated ZFP64 demethylation activates CENPL to promote epithelial ovarian cancer progression

CEP55 Positively Affects Tumorigenesis of Esophageal Squamous Cell Carcinoma and Is Correlated with Poor Prognosis

ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer

ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer

High expression of AlkB homolog 5 suppresses the progression of non‐small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11

CEP55: Implications for Immunotherapy and Survival in Hepatocellular Carcinoma

High expression levels of centromere protein O participates in cell proliferation of human ovarian cancer

ALKBH5 Inhibits Cancer Cell Proliferation in Prostate Cancer through KLF4/TERT Signaling

ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells

N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression

Data on the Association of Cmpk1 with Clinicopathological Features and Biological Effect in Human Epithelial Ovarian Cancer